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Abstract We recently demonstrated that the mouse EP3[~ 
receptor and its carboxyi-terminal tail-truncated receptor 
showed agonist-dependent and full constitutive Gi activities, 
respectively (Hasegawa, H., Negishi, M. and Ichikawa, A. 
(1996) J. Biol. Chem. 271, 1857-1860). To assess the role of the 
carboxyl-terminal tail in the EP3[~ receptor Gi coupling, we 
constructed a series of mutant receptors with progressively 
truncated carboxyl-termini. The truncated receptors displayed 
constitutive Gi activities, the degree of constitutive activity 
basically correlating with the inverse of the length of the 
carboxyl-terminal tail, but the sequence between Leu340 and 
Va1347 was mainly contributed to the constitutive activity. Thus, 
the carboxyl-terminal tail plays an important role in the 
constraint of the EP3 receptor in its inactive conformation. 
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stitutive activity [7,8]. In addition, the COOH-terminal tail- 
truncated receptor showed only agonist-independent constitu- 
tive Gi activity, suggesting that the core of the EP3 receptor 
has ability to associate with and activate Gi and the COOH- 
terminal tails after the alternative splicing site suppress the 
activation of Gi by the EP3 receptor [7]. This idea was re- 
cently supported by the finding that the human EP3 receptor 
isoforms showed constitutive Gi activity in various degrees 
and truncation of the COOH-terminal tail induced complete 
constitutive activity [9]. Among three isoforms, the EP3[~ re- 
ceptor showed no constitutive activity, indicating that the 
COOH-terminal tail of the EP313 receptor has the strongest 
ability to suppress the Gi activation by the EP3 receptor. To 
assess the role of the COOH-terminal tail of the EP313 recep- 
tor in Gi coupling, we constructed a series of mutant receptors 
with progressively truncated COOH-termini, and examined 
structural determinant of the tail for the suppression of the 
receptor-mediated Gi activation. 
I. Introduction 
2. Materials and methods 
The interaction of cell surface hormone receptors with het- 
erotrimeric G proteins is crucial for hormonal actions [1]. 
Most G protein-coupled rhodopsin-type receptors hare con- 
served structural features, consisting of seven transmembrane- 
spanning domains and three intracellular loops and one 
COOH-terminal tail [2]. The domains of the receptors which 
interact with and activate G proteins have been extensively 
studied, and specific regions in the second and third intracel- 
lular loops were shown to function in G protein coupling [3]. 
However, precise molecular mechanisms for regulation of the 
receptor-induced G protein activation are still poorly under- 
stood. 
We have cloned the mouse prostaglandin (PG) EP3 recep- 
tor and demonstrated that this receptor is a G protein-coupled 
rhodopsin-type receptor that engages in inhibition of aden- 
ylate cyclase [4]. Furthermore, we identified the three isoforms 
of the mouse EP3 receptor, EP3c~, 13, and y, with different 
COOH-terminal tail, which were produced through alterna- 
tive splicing [5,6] and differed in agonist-independent constit- 
utive Gi activity; the EP3a receptor showed marked agonist- 
independent Gi activity, the EP313 receptor had no constitu- 
tive activity, and the EP35' receptor showed mostly full con- 
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2.1. Materials 
M&B 28767 was a generous gilt from Dr. M.P.L. Caton of Rhone- 
Poulenc Ltd. [5,6,8,11,12,14,15-aH]PGE2 (181 Ci/mmol) and a ~51- 
labeled cAMP assay system were obtained from Amersham Corp.; 
GTPTS was from Boehringer Mannheim: and forskolin was from 
Sigma. 
2.2. Construction and stable expression 1'the mutant reeeptors 
Progressively truncated receptor cDNAs were constructed by means 
of a polymerase chain reaction-mediated mutagenesis technique [10], 
using cDNA for EP318 [5] as a template, cDNAs for mutated recep- 
tors, T339, T347, and T355, which encode receptors that terminate 
after Asn339, Va1347, and Ile355, respectively, were prepared by cre- 
ating a stop codon immediately after the codon encoding respective 
residues. The mutated regions in the cDNAs were sequenced [11]. 
cDNAs were transfected into Chinese hamster ovary (CHO) cells 
and stable transformants were cloned as described previously [5].
2.3. Measurement q[' cA MP formation 
Cyclic AMP levels in CHO cells were determined as reported pre- 
viously [12]. The receptor-expressing CHO cells cultured in 24-well 
plates (5× 10 '5 cells/well) were washed with HEPES-buffered saline 
containing 140 mM NaC1, 4.7 mM KC1, 2.2 mM CaCI> 1.2 mM 
MgCI> 1.2 mM KH2PO4, 11 mM glucose, and 15 mM HEPES, pH 
7.4, and preincubated for 10 rain. Reactions were started by the ad- 
dition of test agents along with 100 laM Ro-20-1724. After incubation 
for 10 min at 37°C, reactions were terminated by the addition of 10% 
trichloroacetic acid. The content of cAMP in the cells was measured 
by radioimmunoassay with an Amersham cAMP assay system. 
2.4. PGE2-binding assay, 
The harvested CHO cells expressing each receptor were homogen- 
ized using a Potter-Elvehjem homogenizer in 20 mM Tris-HC1 (pH 
7.5), containing 10 mM MgCI> 1 mM EDTA, 20 btM indomethacin 
and 0.1 mM phenylmethylsulfonyl fluoride. After centrifugation at 
250000×g for 20 min, the pellet was washed, suspended in 20 mM 
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Mes-NaOH (pH 6.0) containing 10 mM MgC12 and 1 mM EDTA, 
and was used for the [3H]PGE2-binding assay. The membrane (50 ~tg) 
was incubated with various concentrations of [3H]PGE2 in the pres- 
ence or absence of 100 ~tM GTPyS at 30°C for l h, and [3H]PGE2 
binding to the membrane was determined as described previously [13]. 
Nonspecific binding was determined using a 1000-fold excess of un- 
labeled PGE2 in the incubation mixture. The specific binding was 
calculated by subtracting the nonspecific binding from the total bind- 
ing. 
3. Resu l t s  and d iscuss ion 
A series of mutant EP3 receptors were constructed in which 
stop codons were inserted at similar spaced intervals through- 
out the COOH-terminal tail after the splicing site (Fig. 1), and 
we chose the CHO cell lines stably expressing each mutant 
receptor, T339, T347, T355, showing receptor numbers imilar 
to those of the EP313 receptor and T335, which had been 
established previously [5,14] (EP313, 365+8.3 fmol/mg; 
T355, 408+1.1 fmol/mg; T347, 505+6.0 fmol/mg; T339, 
386_+3.1 fmol/mg; T335, 362+ 13 fmol/mg). We tested the 
ability of the wild-type and mutant EP313 receptors to inhibit 
the forskolin-activated adenylate cyclase in the presence or 
absence of an EP3 agonist, M&B 28767, and compared their 
abilities (Fig. 2). In the absence of the agonist, forskolin in- 
creased the intracellular cAMP levels in the order of 
EP313 > T347-  T355 > T339 > T335. Increasing concentra- 
tions of M&B 28767 caused a decrease in the forskolin-stimu- 
lated cAMP formation in the EP313 receptor, T347, T355, and 
T339, but this decrease was not observed in T335. The cAMP 
level of T335 in the presence of the agonist was significantly 
higher than the levels maximally reduced by the agonist in 
other mutant receptors and EP3I] receptor. Similar result 
has been observed with the COOH-terminal tail-truncated 
human EP3 receptor [9]. These results indicate that the 
EP313 receptor has no constitutive activity, T347 and T355 
are partially constitutive, T339 is mostly constitutive and 
T335 is completely constitutive in Gi activity. We examined 
several clones of T335 with different expression levels, but 
they showed fully constitutive Gi activity (data not shown). 
We transiently transfected HEK293 cells with the EP3~ and 
T335 receptors, and they showed agonist-dependent a d con- 
stitutive Gi activity in HEK293 cells, respectively (data not 
shown). Thus, the degree of constitutive activity basically cor- 
related with the inverse of the length of the COOH-terminal 
tail. However, the sequence from Leu340 to Va1347, within 
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Fig. 1. Schematic depiction of structure of truncated EP313 recep- 
tors. The COOH-terminal tail of EP3!3 receptor after the splicing 
site was shown by the single-letter code for amino acid residues. 
The truncation sites are shown as black bars. 
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Fig. 2. Inhibition of adenylate cyclase by the EP3I] receptor and 
four mutant receptors. CHO cells expressing EP313 (D), T347 (zx), 
T355 (A), T339 (e), or T335 receptor (©) were incubated at 37°C 
for 10 min with 10 /aM forskolin in the presence or absence of the 
indicated concentrations f M&B 28767, then cAMP contents were 
determined as described in Section 2. The results shown are the 
means +_ S.E.M. for triplicate determinations. 
the COOH-terminal tail, is strongly contributed to the 
COOH-terminal tail-induced suppression of the core of the 
EP3 receptor-mediated Gi activation, because the truncation 
from Va1347 to Leu340 caused marked constitutive Gi activa- 
tion. 
The interaction of receptors and G proteins can be exam- 
ined by investigating modulation of the binding affinity of 
receptors by guanine nucleotides [15]. In contrast o intact 
cells, in the broken cell membranes, receptors with potentially 
active conformation i a basal condition can associate with G 
proteins and promote he release of GDP from the G proteins 
and form the stable complex of agonist-receptor-nucleotide- 
free G protein in the absence of GTP. When high concentra- 
tion of nonhydrolyzable GTP, GTPyS, is added, GTPyS 
strongly binds to G proteins and destabilizes the complex, 
promoting the release of G protein from the complex, then 
all receptors how G protein-free form [16]. In in vitro mem- 
brane experiments, receptors cannot turn activation cycle of G 
proteins in the absence of GTP, and thus the experimental 
results show the receptors with an initial transient conforma- 
tion. In intact cells, agonists increase the percentage of active 
form of receptors. We then examined the effects of GTPTS on 
PGE2-binding affinities of the EP313 receptor (agonist depend- 
ently active receptor) and T335 (constitutively active recep- 
tor). Fig. 3 shows the Scatchard analysis of PGE2 binding 
to membrane xpressing each receptor in the presence or ab- 
sence of GTPyS. The EP3~ receptor had a single high-affinity 
binding site in the absence of GTPTS (Kd=2.5 nM; 
Bm~ = 365 fmol/mg). GTPyS did not affect the affinity of 
the receptor (Kd = 2.5 nM; Bm~, = 355 fmol/mg), On the other 
hand, the PGE2-binding affinity of T335 showed high-affinity 
(Kdu = 1.0 nM; Bm~n = 65.0 fmol/mg) and low-affinity states 
(KdL ----61 riM; BIn~L = 266 fmol/mg) and the majority of T335 
was the low-affinity state, as reported previously [14]. The 
addition of GTP~S increased the number of T335 in the 
high-affinity state (Kdn =0.83 nM; Bm~n =220 fmol/mg) and 
decreased the number in the low-affinity state (KdL----82 riM; 
Bm~L -- 82.5 fmol/mg) without any change in the total number 
H. Hizaki et al./FEBS Letters 414 (1997) 323~26 325 
(A) EP313 (B) T335 
200 250 / '= ' ' ' 
/ W" '-' " '11 
/ ,,, "~ 2°°~ O * GTP¥S "1 I 200 
150~ O 0~ - N°ne" t l  o~ Elo 
100 I" • "'".'~=t~ . .0 2s so 7s lOO I 
J " '~  [3 H]'PGE 2 (nM, ] 100 
~ 50 I  +GTPTS"~:ne  ] 5o 
111 0 0 
0 100 200 300 400 0 100 200 300 
Bound (fmol/mg) 
Fig. 3. Scatchard analysis of PGE2 binding to the membrane of CHO cells expressing theEP3[~ or T335 receptor. The membrane fraction of 
CHO cells expressing the EP3~ receptor (A) or T335 receptor (B) was incubated for 60 min at 30°C with increasing concentrations of 
[sH]PGE2 in the presence ( ) or absence (©) of 100 ~M GTPyS. The specific binding of [:~H]PGE2 was determined as described in Section 2. 
The Scatchard plot was transformed from the values of specific [3H]PGE2 binding (inset). The results hown are the means for triplicate deter- 
minations. 
of receptor or in the Kd values of the high-affinity and low- 
affinity states, indicating that GTPyS converted the receptor 
from its low-affinity state to the high-affinity state. Most hor- 
mone receptors how high affinity in a G protein-coupled 
form and low affinity in a form not associated with G pro- 
teins, and guanine nucleotides cause the dissociation of the G 
proteins from the receptor G protein complex, leading to the 
transition of the receptors from a high-affinity state to a low- 
affinity state [15]. In contrast with most receptors, GTP'/S 
induced the inverse transition for T335. This means that 
T335 shows low affinity in the complex form with the G 
protein but shows high affinity in the form not associated 
with the G protein. Since T335 shows the constitutive Gi 
activity and is mainly low-affinity state, most of the T335 
receptor constitutively associates with Gi. In intact cells, 
T335 receptor promotes the activation cycle of Gi in the ab- 
sence of agonists. On the other hand, the EP3[~ receptor 
shows the agonist-dependent Gi activity and high-affinity 
state. Thus, it is assumed that the EP313 receptor is the form 
not associated with Gi and thus is insensitive to GTP'/S. 
Considering these findings, the EP3 receptor has a unique 
feature in guanine nucleotide sensitivity: the EP3 receptor 
shows a high affinity in the G protein-free form and guanine 
nucleotides increase the agonist-binding affinity. Therefore, 
the ratio of the G protein-associated and G protein-free 
EP3 receptors can be inferred from the sensitivity to guanine 
nucleotides. We next examined the effects of GTP'/S on the 
PGE2 binding to wild-type and mutant EP3 receptors. As 
shown in Fig. 4, GTPyS did not affect the PGE2 binding to 
T355 as well as the EP3~ receptor, but GTPTS slightly in- 
creased the binding to T347. On the other hand, GTPyS 
markedly enhanced the binding to T339 and T335. This result 
indicates that the progressive truncation of the COOH-termi- 
nal tail of the EP3~ receptor increases the percentage of the 
receptor constitutively associated with the G protein with a 
low-binding affinity for PGE2 but the truncation up to Leu340 
induces a marked increase in this percentage. This pattern of 
GTPTS sensitivity is consistent with the levels of constitutive 
Gi activity of the progressively truncated receptors. 
Lefkowitz and co-workers have proposed a two-state model 
in which receptors are in equilibrium between the inactive 
form and the active form that can associate with and activate 
G protein [17]. Gi activity of the EP313 receptor is completely 
agonist dependent, and the EP3[~ receptor shows high-affinity 
state, which does not associate with G protein (Figs. 2 and 3). 
Therefore, the equilibrium of the EP3~ receptor basically 
shifts toward the inactive conformation i the absence of ag- 
onists, and the COOH-terminal tail after the alternative splic- 
ing site suppresses activation of Gi by the EP3~ receptor and 
has strong potency in the constraint of the receptor in its 
inactive conformation. In intact cells, agonists move the equi- 
librium to the rightward irection and increase the percentage 
of active conformation. When the COOH-terminal tail is trnn- 
cated, the equilibrium of the receptor shifts toward the active 
conformation, showing the G protein-associated low-affinity 
state, which displays constitutive activity. The COOH-termi- 
nal tail may regulate the equilibrium between the inactive and 
active conformations. Since the degree of constitutive activity 
basically correlated with the inverse of the length of the 
COOH-terminal tail, the length of the tail is one of the im- 
portant determinants for the constraint of the receptor in the 
inactive form. In addition, the region between Leu340 and 
Va1347 may play the most important role in the suppression, 
because marked increases in constitutive Gi activity and 
GTP'/S sensitivity were observed with truncation of this re- 
gion. 
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Fig. 4. Effect of GTPTS on [ZH]PGE2 binding to the EP313 receptor 
and four mutant receptors. The membrane of CHO cells expressing 
the EP3~3, T355, T347, T339, or T335 receptor was incubated with 
4 nM [3H]PGE2 in the presence (I) or absence ([]) of 100 I.tM 
GTP'/S. Specific [3H]PGE2 binding was determined as described in 
Section 2. The results shown are the means+S.E.M, for triplicate 
determinations. 
In summary, we here demonstrated that inhibition of the 
EP313 receptor-mediated Gi activity by the COOH-terminal 
tail is basically regulated by the length of the tail but the 
region from Leu340 to Va1347 plays the most important 
role in this inhibition. This study will help to elucidate the 
molecular mechanism of G protein activation induced by re- 
ceptors. 
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